Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF) reported that the randomized CAPTAIN trial met its prespecified primary safety endpoint: preservation of erectile function and urinary continence at 6 months favored the TULSA Procedure 50% vs robotic radical prostatectomy (RP) 24% (p<0.05, RR 2.1).
CAPTAIN enrolled 211 patients across 23 sites. Key benefits after TULSA included 84% pad-free continence, 56% erectile function, zero median blood loss, shorter hospital stay, fewer hospitalizations (0.7% vs 6.3%), and faster return to work. 12-month TULSA oncologic data are pending.
Profound Medical (NASDAQ:PROF) announced that the first clinical outcomes from the Level 1 post‑market CAPTAIN trial comparing the TULSA Procedure with robotic radical prostatectomy will be presented at EAU 2026 on March 13, 2026 at 9:40 a.m. EDT.
Profound will issue a follow-up press release and host an investor webinar at 11:30 a.m. EDT on March 13 where Dr. Laurence Klotz will review CAPTAIN data; management will also hold one‑on‑one meetings at the ROTH Conference March 22–24, 2026 in Dana Point, CA.
Profound Medical (NASDAQ:PROF) reported record Q4-2025 revenue of $6.0M, up 43% year-over-year and 13% sequentially, and full-year 2025 revenue of $16.1M. Installed base stood at 78 systems with a pipeline of 110 potential new systems and an expectation of ~120 installs by end-2026. The company closed equity financings totaling $42.45M in Dec 2025, ended the year with $59.7M cash, and reported a full-year net loss of $42.6M (GAAP). Notable operational milestones include CMS reimbursement at Urology APC Level 7, launch of TULSA-AI for BPH, and selected late-breaking CAPTAIN trial outcomes presentation in March 2026.
Profound Medical (NASDAQ:PROF) will release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and business developments. A live webcast and archived recording will be available in the company Investors section.
Profound Medical (NASDAQ:PROF) received INOVAIT’s 2025–2026 Mount Logan Award for the TULSA Procedure™ and its commercial milestones. Key highlights include treating the 4,000th TULSA patient, securing new U.S. Medicare reimbursement codes, regaining exclusive Canadian distribution rights, and expanding global access via partnerships and a North America direct sales team.
The TULSA-PRO® system uses robotically controlled directional ultrasound with real-time MRI thermography to heat prostate tissue precisely, aiming to minimize blood loss, hospital stays, and common surgery or radiation side effects.
Profound Medical (NASDAQ:PROF) announced that PRO FAMILIA Specialist Hospital in Rzeszów, Poland completed its 500th Sonalleve procedure on Feb 5, 2026, marking a commercial milestone for the incision-free, MRI-guided uterine therapy.
The company reports 10 Sonalleve devices currently operational across Europe, China and Southeast Asia, with over 4,000 women treated and approximately $10 million in research grants awarded in the past five years to support clinical studies.
Profound notes Sonalleve is mainly sold as a one-time capital purchase and is seeing growth internationally while U.S. commercialization focus remains on TULSA-PRO.
Profound Medical (NASDAQ:PROF) will participate in two investor events in February 2026: the Lake Street Life-Sciences Invitational on Feb 4–5 in Scottsdale, AZ, and the BTIG 13th Annual MedTech conference on Feb 10–11 in Snowbird, UT. No webcasts will be available due to event formats.
Profound Medical (NASDAQ:PROF) announced that Mount Sinai Hospital performed its first incision-free, MRI-guided TULSA Procedure for prostate disease on Jan 15, 2026, making Mount Sinai the first health system in the New York Metro Area to offer TULSA-PRO.
The robotically controlled ultrasound system heats tissue to a kill temperature of 55–57°C with real-time MRI thermography and autonomous temperature adjustment, enabling tailored ablation with no procedural blood loss, same-day discharge, and intent to minimize urinary incontinence and erectile dysfunction versus surgery or radiation.
Mount Sinai is ranked No. 6 nationally for Urology (2025–26), and hospital clinicians plan future studies and guideline work using TULSA-PRO.
Profound (NASDAQ:PROF) reported its year-end TULSA-PRO installed base reached 78 systems as of December 31, 2025, exceeding its goal of 75 installs for 2025. The company also said its qualified sales pipeline grew to 97 new systems classified in the "Verify, Negotiate and Contracting" stages at year-end. Management linked the larger installed base to expectations of higher patient treatment rates and growth in recurring revenue tied to procedures, and noted upcoming Q4 and full-year 2025 financial results due near the end of February 2026.
Profound Medical (NASDAQ:PROF) announced that Johns Hopkins Hospital treated its first commercial (non‑clinical‑trial) prostate cancer patient using the TULSA-PRO system on Jan 6, 2026.
The milestone coincides with the opening of Johns Hopkins Medicine's new interventional MRI (iMRI) suite and underscores adoption of MRI-guided, incision‑free prostate ablation. The company notes TULSA-PRO uses robotically controlled directional ultrasound plus real‑time MRI thermography to target tissue, aiming for no procedural blood loss, no overnight stay, and reduced side effects versus surgery or radiation. The summary also cites prior participation in the TACT pivotal trial that led to FDA clearance.